Posted by Michael Wonder on 19 Apr 2017
NICE publishes second appraisal consultation document for cabozantinib maleate
19 April 2017 - The Department of Health has asked NICE to produce guidance on the use of cabozantinib in the NHS in England by adult patients with advanced renal cell carcinoma.
Cabozantinib is not recommended within its marketing authorisation for treating advanced renal cell carcinoma in adults after vascular endothelial growth factor targeted therapy.
